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ABSTRACT Endothelial nitric oxide synthase (eNOS)–mediated NO production plays a critical 
role in the regulation of vascular function and pathophysiology. Caveolin-1 (Cav-1) binding to 
eNOS holds eNOS in an inactive conformation; however, the mechanism of Cav-1–mediated 
inhibition of activated eNOS is unclear. Here the role of Src-dependent Cav-1 phosphoryla-
tion in eNOS negative feedback regulation is investigated. Using fluorescence resonance 
energy transfer (FRET) and coimmunoprecipitation analyses, we observed increased interac-
tion between eNOS and Cav-1 following stimulation of endothelial cells with thrombin, vas-
cular endothelial growth factor, and Ca2+ ionophore A23187, which is corroborated in isolated 
perfused mouse lung. The eNOS/Cav-1 interaction is blocked by eNOS inhibitor l-NG-
nitroarginine methyl ester (hydrochloride) and Src kinase inhibitor 4-amino-5-(4-chlorophenyl)-
7-(t-butyl) pyrazolo [3, 4-d] pyrimidine. We also observe increased binding of phosphomimick-
ing Y14D-Cav-1 mutant transduced in human embryonic kidney cells overexpressing eNOS 
and reduced Ca2+-induced NO production compared to cells expressing the phosphodefec-
tive Y14F-Cav-1 mutant. Finally, Src FRET biosensor, eNOS small interfering RNA, and NO 
donor studies demonstrate NO-induced Src activation and Cav-1 phosphorylation at Tyr-14, 
resulting in increased eNOS/Cav-1 interaction and inhibition of eNOS activity. Taken together, 
these data suggest that activation of eNOS promotes Src-dependent Cav-1–Tyr-14 phospho-
rylation and eNOS/Cav-1 binding, that is, eNOS feedback inhibition.
INTRODUCTION
Production of nitric oxide (NO) by endothelial cell nitric oxide syn-
thase (eNOS; NOS3) regulates vascular tone, blood flow, leukocyte-
endothelial interactions, platelet adhesion and aggregation, and 
vascular smooth muscle cell proliferation (Sessa, 2004; Atochin and 
Huang, 2010). Studies demonstrated direct interaction of eNOS 
with caveolin-1 (Cav-1; Feron et al., 1996; García-Cardeña et al., 
1996) and that Cav-1 functions as an endogenous negative regula-
tor of eNOS activity (Drab et al., 2001; Razani et al., 2001; Zhao 
et al., 2002; Wunderlich et al., 2006; Maniatis et al., 2008). Specifi-
cally, eNOS binds to the caveolin scaffold domain (CSD; amino ac-
ids 82–101; García-Cardeña et al., 1997; Bucci et al., 2000), and ala-
nine scanning of the CSD identified Thr-90 and -91 and Phe-92 as 
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inhibition of eNOS activity. However, the 
molecular mechanisms responsible for re-
storing eNOS enzymatic activity to its basal 
state and whether its binding to Cav-1 is im-
portant in this process have not been estab-
lished. In the present study, we tested the 
hypothesis that in endothelial cells, there is 
an intrinsic NO-dependent mechanism of 
eNOS negative feedback regulation depen-
dent on phospho–Cav-1 binding.
RESULTS
Kinetics of interaction between 
eNOS and Cav-1
To assess spatial and temporal eNOS and 
Cav-1 binding, CHO cells were transfected 
with fluorescent protein conjugates, and 
stimulation-dependent fluorescence reso-
nance energy transfer (FRET) was deter-
mined. A typical FRET image observed 
upon stimulation with 5 μM Ca2+ ionophore 
A23187 is shown in Figure 1A. Fluorescence 
intensity of eNOS–cyan fluorescent protein 
(CFP; donor) decreased, whereas Cav-1–
yellow fluorescent protein (YFP; acceptor) 
increased in the region of interest (ROI; 
white box), indicating increased FRET from 
eNOS to Cav-1 was induced by increased 
intracellular Ca2+ (Figure 1A). After the cells 
were treated with 5 μM A23187, we ob-
served Cav-1–eNOS FRET that peaked 
1.5 min after stimulation and remained ele-
vated for 5 min (Figure 1B). Following throm-
bin (4 U/ml) treatment, Cav-1–eNOS FRET 
was also increased at 5 min (Figure 1B). Im-
munoprecipitation experiments showed 
that Cav-1–YFP binding to eNOS-CFP in-
creased 10-fold 1 min after addition of 
A23187 and 5-fold 1 min after stimulation 
with thrombin compared with medium alone 
(Figure 1, C and D). To ensure that the ex-
pressed fluorescent Cav-1 and eNOS pro-
teins were functional, CHO cells stably ex-
pressing Cav-1–YFP and eNOS–CFP were 
stimulated with A23187 or thrombin, and Western blotting was used 
to assess the phosphorylation state of Cav-1 and eNOS (Figure 1, 
E–G). Thus Cav-1 and eNOS phosphorylation increased in parallel 
with the increase in coimmunoprecipitation (coIP).
Cav-1/eNOS interaction in mouse lung treated with A23187
To assess the in vivo reality of the foregoing observations, we inves-
tigated eNOS and Cav-1 interaction in intact vessels of isolated 
mouse lungs perfused with 5 μM A23187 via pulmonary artery can-
nula. The whole-lung homogenates were prepared and immuno-
precipitated with anti–Cav-1 antibody and probed for both Cav-1 
and eNOS (Figure 2A). eNOS binding to Cav-1 increased sixfold 
after 3 min of treatment with A23187 (Figure 2B). Phosphorylation of 
eNOS (Ser-1177) increased about fourfold at 3 min following treat-
ment with 5 μM A23187 and then declined compared with medium 
alone. However, phosphorylation of Src (Tyr-418) and Cav-1 (Tyr-14) 
continued to increase through 10 min after addition of 5 μM A23187 
in mouse lungs (Figure 2, C and D).
being critical for eNOS binding and inhibition (Bernatchez et al., 
2005, 2011). On stimulus-dependent activation of endothelial cells, 
Cav-1–mediated negative regulation of eNOS can be overcome by 
Ca2+-calmodulin (CaM), thus increasing eNOS activity (Michel et al., 
1997a, 1997b). In contrast, eNOS translocation to internal mem-
branes and CaM dissociation were proposed to participate in the 
mechanism of eNOS inhibition (Dudzinski and Michel, 2007).
Dudzinski and Michel (2007) proposed that eNOS is negatively 
regulated by posttranslational lipid modification. Quiescent eNOS 
is anchored to the caveolar membrane by myristoylation, and thus 
upon stimulus-dependent activation, Cav-1 binding may be dis-
placed by Ca2+-CaM, enabling eNOS activation. eNOS is then be-
lieved to translocate from caveolae to internal membranes, where 
CaM dissociates, allowing for eNOS reassociation with Cav-1. 
Müller-Esterl’s lab and also Barrett and coworkers proposed that fol-
lowing activation, eNOS translocation back to caveolae results in 
eNOS inactivation (Oess et al., 2006; Wang et al., 2009). Both of 
these mechanisms predict that eNOS binding to Cav-1 leads to 
FIGURE 1: Interaction of Cav-1 and eNOS determined by FRET and coIP. (A) Typical FRET 
image of Cav-1–YFP and eNOS–CFP expressed in CHO cells. Note that the fluorescence 
intensity of YFP increases, whereas CFP decreases in the ROI (white box) after addition of 5 μM 
Ca2+ ionophore A23187. Bar, 10 μm. (B) Normalized FRET measurements in CHO cells 
expressing Cav-1–YFP and eNOS–CFP after treatment with 5 μM A23187 (mean ± SEM; n = 12) 
or 4 U/ml thrombin (mean ± SEM; n = 5). YFP/CFP was normalized as 1 by the value at time zero 
(*p < 0.01 for all times beyond 2 min after thrombin addition; **p < 0.005 for all times beyond 
1.5 min after A23187). (C) CoIP between Cav-1–YFP and eNOS–CFP in CHO cells (mean ± SEM; 
n = 3). (D) Normalized data of coIP (ratio of eNOS-CFP/Cav-1-YFP after IP with anti–Cav-1 
antibody; *p < 0.05). (E) Phosphorylation of Cav-1–YFP and eNOS–CFP in CHO cells after 
treatment with 5 μM A23187 or 4 U/ml thrombin (mean ± SEM; n = 3). Ratio of phosphorylated/
total protein at 0 min was set as 1 (*p < 0.05).
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action required eNOS and Cav-1 phosphory-
lation. HUVECs were lysed and prepared for 
IP by anti–p-Ser-1177-eNOS antibody (Figure 
3C) under the same conditions as described 
earlier (Figure 3, A and B). p-Ser-1177-eNOS 
phosphorylation increased following iono-
phore stimulation, and the amount of p-Tyr-
14-Cav-1 (relative to the amount of total Cav-
1) that coimmunoprecipitated with p-Ser-
1177-eNOS also increased fivefold relative 
to vehicle-treated control cells (Figure 3D).
We next determined the effect of eNOS 
inhibitor l-NG-nitroarginine methyl ester 
(hydrochloride) (l-NAME) and Src kinase in-
hibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) 
pyra zolo [3, 4-d] pyrimidine (PP2) on the 
A23187-induced eNOS/Cav-1 interaction. 
Confluent HUVEC cultures were pretreated 
with medium alone, 1 mM l-NAME, or 15 μM 
PP2 for 30 min at 37°C, and then 5 μM 
A23187 was added to cells and incubated for 
another 5 min. eNOS, Src, and Cav-1 phos-
phorylation increased significantly to 4.4-, 
1.3-, and 2.6-fold of vehicle-treated cells 
(1.0 relative unit [R.U.]), respectively (Figure 
3E). Pretreatment with l-NAME significantly 
decreased ionophore-induced increase in 
Src p-Tyr-418 by 51% (from 0.337 ± 0.067 to 
0.164 ± 0.094 R.U. above vehicle-treated 
cells; p < 0.05; n = 9) and p-Tyr-14-Cav-1 by 
68%, whereas PP2 prevented A23187-
induced phosphorylation of Src and Cav-1. 
eNOS–Ser-1177 phosphorylation induced by 
A23187 was not significantly affected by either PP2 or l-NAME. CoIP 
experiments showed that eNOS binding to Cav-1 increased eightfold 
after 5 min treatment with 5 μM A23187 compared with medium 
alone, and, of interest, both l-NAME and PP2 significantly reduced 
the interaction between eNOS and Cav-1 (Figure 3F). Thus, PP2 inhi-
bition of Src activity and Cav-1 phosphorylation, as well as l-NAME 
inhibition of eNOS activity, significantly blocked Ca2+-induced eNOS/
Cav-1 binding in endothelial cells.
In additional studies, we assessed the role of various kinases, in-
cluding Akt, PKA, AMPK, and CaMKII, in the mechanism of eNOS 
phosphorylation/activation in HUVECs stimulated with Ca2+ iono-
phore A23187 (Supplemental Figure S4). On stimulation, p-eNOS 
(Ser-1177) and p-Cav-1 (Tyr-14) peaked within 3–5 min, whereas 
pAkt–Thr-308 was maximal at 20 min and Akt–pSer-473 was maxi-
mal at 60 min (Supplemental Figure S4, A–E). Thus eNOS activation 
occurred at a faster rate than Akt activation, leading us to conclude 
that Akt does not play a significant role in the early phase of Ca2+-
induced eNOS activation. Furthermore, we assessed eNOS–
Ser-1177 phosphorylation induced by A23187 following 30 min of 
pretreatment of cells with 10 μM H89 (PKA inhibitor), 30 μM 5-iodo-
tubercidin (AMPK inhibitor), or 10 μM STO-609 (CaMKII inhibitor). 
We observed that only the CaMKII inhibitor STO-609 significantly 
blocked Ca2+-induced eNOS–Ser-1177 phosphorylation by 50% 
(Supplemental Figure S4, F and G).
p-Tyr-14-Cav-1 promotes eNOS binding and decreases 
eNOS activity
To further clarify the role of Cav-1 versus eNOS phosphorylation 
in enhanced binding of eNOS to Cav-1, we coexpressed either 
Cav-1 and eNOS phosphorylation induces 
Cav-1/eNOS interaction
Stimulation of human umbilical vascular endothelial cells (HUVECs) 
with 5 μM A23187, 4 U/ml thrombin, or 20 ng/ml vascular endothe-
lial growth factor (VEGF) increased eNOS activity, as measured by 
4,5-diaminofluorescein-2 diacetate (DAF-2 DA) fluorescence inten-
sity, by 7.2-, 6.5-, and 4.6-fold, respectively, over untreated HUVECs 
(Supplemental Figure S1A). NO release was maximal 1 min after 
addition of 5 μM A23187, returning toward prestimulation levels by 
3 min, and was near basal thereafter (Supplemental Figure S1B). 
eNOS–Ser-1177 phosphorylation also increased upon stimulation, 
reaching maximal levels after 3 min (thrombin, 6.0-fold increase; 
A23187, 5.0-fold; VEGF, 3.9-fold), and then decreased over the next 
30 min (Figure 3A). Cav-1–Tyr-14 phosphorylation also increased but 
at a slower rate than that of eNOS (Figure 3A). The interaction be-
tween eNOS and Cav-1 after stimulation of HUVECs was also as-
sessed by coIP (Figure 3B). Enhanced eNOS–Cav-1 association was 
observed within 1 min of stimulation with A23187, peaked at 5 min 
(a 5-fold increase compared with untreated cells), and remained el-
evated at 2.5-fold above baseline at 30 min (Figure 3B).
For Western blots and IP experiments, we isolated total mem-
brane fractions (Supplemental Figure S2) as described in Materials 
and Methods, which contained virtually all of the eNOS and Cav-1 
protein relative to membrane-enriched fractions used in previous 
studies (Busconi and Michel, 1993; Feron et al., 1998). As expected, 
we also observed increased CaM coIP with eNOS following addition 
of A23187 (Supplemental Figure S3).
Because both eNOS and Cav-1 phosphorylation increased upon 
stimulation with A23187, we addressed whether eNOS/Cav-1 inter-
FIGURE 2: CoIP between eNOS and Cav-1 in mouse lung. (A) Mouse lungs were perfused with 
medium containing 5 μM A23187 for 0, 3, and 10 min. Lungs were then homogenized and 
prepared for IP with polyclonal anti–Cav-1. (B) Normalized coIP data (mean ± SEM; n = 4); ratio 
of eNOS/Cav-1 at 0 min was set as 1 (*p < 0.05). (C) Phosphorylation of eNOS–Ser-1177, 
Src–Tyr-418, and Cav-1–Tyr-14 (indicated by arrows) in mouse lung homogenates following 
A23187 treatment (D). Normalized ratio of phosphorylated/total protein, with time 0 set as 1 
(*p < 0.05; mean ± SEM; n = 4).
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These experiments involved the transient 
transfection of WT-eNOS-CFP, eNOS-
S1177D-CFP, and eNOS-S1177A-CFP in 
HEK cells stably expressing WT-Cav-1-YFP, 
Y14D-Cav-1-YFP, or Y14F-Cav-1-YFP. Cells 
were lysed 48 h after transfection and im-
munoprecipitated with anti–Cav-1 antibody. 
Both eNOS and Cav-1 were measured by 
Western blot after IP (Figure 4A), and the 
data from three separate experiments were 
averaged as shown in the bar graph. We ob-
served Y14D-Cav-1 binding to either WT-
eNOS or S1177D-eNOS to be equivalent 
but 4.2-fold greater than the binding of WT-
eNOS and WT-Cav-1, indicating that Cav-1 
phosphorylation is an important determi-
nant of eNOS binding. Moreover, binding of 
the phosphodefective S1177A-eNOS mu-
tant to WT- or Y14D-Cav-1 was significantly 
reduced, suggesting eNOS phosphoryla-
tion is also an important determinant of the 
binding reaction. Y14F-Cav-1 showed much 
lower binding to all eNOS constructs com-
pared with WT- or Y14D-Cav-1, suggesting 
the phospho-defective Cav-1 conformation 
does not bind well to eNOS (Figure 4A). 
The level of protein expression achieved 
with each Cav-1 and eNOS construct before 
IP was similar, as shown in Figure 4B, and 
coIP of untagged proteins yielded similar 
results.
We next determined whether enhanced 
eNOS binding to p-Tyr-14-Cav-1 affects 
eNOS activity. Nitrite (NO2
−, the stable prod-
uct of NO autoxidation) concentration was 
measured in media from HEK cells stably ex-
pressing WT-eNOS (Supplemental Figure 
S5) following transient transfection with WT-
Cav-1-YFP, Y14D-Cav-1-YFP, and Y14F-Cav-
1-YFP as before. Cells were then treated 
with 5 μM A23187 for 30 min. Compared to 
HEK/eNOS cells, cells transfected with WT-
Cav-1-YFP showed 31% less NO production 
(1.00 ± 0.021 vs. 0.693 ± 0.029 R.U.; p < 
0.001; n = 8). Furthermore, accumulated 
NO2
− in cell culture media was 40% less in 
HEK/eNOS cells transfected with Y14D-
Cav-1 mutant than in WT-Cav-1–expressing 
cells (Figure 4C). To determine the effect of 
Y14D-Cav-1 on eNOS activity, NO2
− produc-
tion per minute per 106 HEK/eNOS cells 
transfected with WT-Cav-1-YFP, Y14D-Cav-
1-YFP, and Y14F-Cav-1-YFP mutants was 
calculated from serial samples. A23187-in-
duced eNOS activation was maximal after 1 
min, returned to near basal activity at 3 min, and then remained low 
at all later time points (Figure 4D), which was similar to the time 
course of NO generation observed in HUVECs (Supplemental Fig-
ure S1B). Importantly, these data indicate that Y14D-Cav-1 limits 
A23187-stimulated eNOS activation compared with cells express-
ing an equivalent level of WT-Cav-1 or phosphodefective Y14F-
Cav-1.
wild-type (WT) Cav-1, phosphomimicking Y14D-Cav-1 mutant, or 
phosphodefective Y14F-Cav-1 mutant in human embryonic kidney 
(HEK) cells together with WT, phosphomimicking (S1177D), or phos-
phodefective (S1177A) eNOS constructs. We then assessed whether 
expression of Y14D-Cav-1 promoted the binding of WT-eNOS as 
compared with phosphodefective eNOS (S1177A) in the absence of 
stimulation. We also measured eNOS activity in each instance. 
FIGURE 3: Phosphorylation-dependent interaction of eNOS and Cav-1 in HUVEC. (A) Time 
course of phosphorylation of eNOS–Ser-1177 and Cav-1–Tyr-14 in HUVECs after addition of 5 μM 
A23187, 4 U/ml thrombin, or 20 ng/ml VEGF (mean ± SEM; n = 6). Normalized data are shown in 
the bottom two rows (*p < 0.05). (B) CoIP of eNOS and Cav-1 in HUVEC after stimulation with 
5 μM A23187 at indicated times (mean ± SEM; n = 4. *p < 0.05; **p < 0.005). (C, D) CoIP of 
phosphorylated eNOS and Cav-1 in HUVECs treated with A23187 for 5 min at 37°C (mean ± 
SEM; n = 3). p-Ser-1177-eNOS antibody was used for IP. Normalized data (p-Tyr-14-Cav-1 vs. 
t-Cav-1 bound to p-eNOS) is shown in D (*p < 0.05). (E) Effects of l-NAME and PP2 on 
phosphorylation of eNOS–Ser-1177, Src–Tyr-418, and Cav-1–Tyr-14 in HUVECs (mean ± SEM; 
n = 9). Confluent HUVECs were pretreated with 1 mM l-NAME or 15 μM PP2 for 30 min at 37°C 
prior to addition of 5 μM A23187 (§p < 0.001; *p < 0.05; and **p < 0.001). (F) Effect of l-NAME 
and PP2 on coIP between eNOS and Cav-1 (mean ± SEM; n = 6) in HUVEC (*p < 0.05; 
**p < 0.005).
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times indicated (Figure 5A). eNOS protein 
expression was significantly reduced after 
eNOS siRNA treatment. In addition, the 
basal p-Tyr-418-Src level was reduced by 
50% in eNOS-depleted cells and remained 
low up to 10 min after addition of A23187 
compared with scrambled siRNA-treated 
cells (Figure 5A). Thus, p-Src was signifi-
cantly lower at each time point in eNOS 
siRNA–treated HUVECs compared with 
scrambled siRNA–treated HUVECs, sug-
gesting that NO production by eNOS in re-
sponse to Ca2+ increases Src activity. We 
speculate that residual Src activation may be 
due to nNOS-derived NO (Bachetti et al., 
2004).
Consistent with this finding, p-Tyr-14-
Cav-1 induced by A23187 stimulation was 
also significantly reduced in HUVECs 
treated with eNOS siRNA (Figure 5A). 
Thus eNOS and NO production lie up-
stream of Src activation and Cav-1 phos-
phorylation. In other experiments, Cav-
1–null mouse embryonic fibroblasts 
(MEFs) were stimulated with 0.2 mM DEA 
NONOate, an NO donor, and lysates were 
probed for p-Tyr-418-Src. As shown in 
Figure 5B, NO donor increased Src activ-
ity by 80% compared with nontreated 
cells, in accord with the finding that eNOS 
expression is an important determinant of 
Src activation. In WT MEFs stimulated 
with DEA-NONOate, we observed a 50% 
increase in pTyr-418-Src, and thus 37% 
less Src activation than observed in WT 
MEFs, consistent with the idea that phos-
phor–Cav-1 plays an important role in the 
mechanism of Src inactivation (Cao et al., 
2002; Place et al., 2011).
To further address the role of NO sig-
naling in the mechanism of Src activation, 
WT-HEK cells and HEK cells stably ex-
pressing eNOS were stimulated with 
A23187. As shown by Western blotting, 
we observed a 66% increase in Src-Tyr-418 
phosphorylation in eNOS-expressing HEK 
cells treated for 5 min with A23187 com-
pared with WT-HEK cells lacking eNOS 
(Figure 5C; n = 7, p < 0.001). NO activa-
tion of Src was also determined using a 
Src FRET biosensor (Figure 5D), which is 
composed of CFP, the Src SH2 domain, a 
flexible linker, a Src substrate peptide, 
and YFP (Wang et al., 2005). On Src acti-
vation, CFP moves away from YFP and FRET decreases. eNOS-
expressing HEK cells transiently transfected with the biosensor 
were imaged by confocal microscopy (a typical FRET image is 
shown in Figure 5D). After stimulation with 5 μM A23187, CFP 
intensity increased, whereas as that of YFP decreased, indicating 
CFP movement away from YFP and thus evidence of increased 
Src kinase activity. Src kinase activity indicated by FRET was 
blocked by l-NAME and PP2 (Figure 5E). As a negative control, 
NO-mediated Src activation stimulates Cav-1 
Tyr-14 phosphorylation
We next addressed the possibility that eNOS-derived NO can itself 
activate Src and mediate tyrosine phosphorylation of Cav-1 needed 
for the inhibitory Cav-1 interaction with eNOS. In this experiment, 
we depleted eNOS in HUVECs with small interfering RNA (siRNA) 
and measured Src activation. eNOS siRNA (100 nM) was added to 
HUVECs, and after 72 h, cells were treated with 5 μM A23187 for the 
FIGURE 4: Binding of Y14D-Cav-1 with eNOS inhibits eNOS activity. (A) CoIP of Cav-1 and 
eNOS mutants in HEK cells. WT-eNOS-CFP, eNOS-S1177D-CFP, and eNOS-S1177A-CFP were 
transiently transfected in HEK cells stably expressing WT-Cav-1-YFP, Cav-1-Y14D-YFP, or 
Cav-1-Y14F-YFP. Cell lysates were immunoprecipitated with anti–Cav-1 pAb 48 h after 
transfection of eNOS mutants in the absence of stimulation. Ratio of WT-eNOS-CFP/wt-Cav-1-
YFP was set at 1 (*p < 0.05; **p < 0.005). Bar graph shows mean ± SEM (n = 3). (B) Protein levels 
of Cav-1 and eNOS mutants in transfected HEK cells before IP. (C) Nitrite accumulation in HEK/
eNOS cells transiently transfected with Cav-1 mutant cDNAs (mean ± SEM; n = 11). Cells were 
treated for 30 min with 5 μM A23187, and supernatants were collected for nitrite assay 
(*p < 0.001). (D) eNOS activity (representative of four independent experiments) of stable HEK/
eNOS cells transiently transfected with Cav-1 mutants.
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Proposed mechanism of 
NO-dependent negative 
feedback inhibition of eNOS
Data shown here indicate that stimulation of 
endothelial cells with calcium ionophore 
A23187, thrombin, or VEGF induces eNOS 
activation and NO-dependent Src activa-
tion. We also observed Cav-1 phosphoryla-
tion and enhanced binding between phos-
pho-Cav-1 and eNOS, which was associated 
with a decrease in eNOS activity. Thus, as 
summarized in Figure 6, we propose a 
mechanism in which phospho–Cav-1 bind-
ing to eNOS decreases eNOS activity. The 
proposed negative feedback mechanism is 
supported by experimental data that show 
that eNOS–Cav-1 interactions (coIP and 
FRET) are blocked by eNOS inhibitor l-
NAME and Src inhibitor PP2 and that phos-
phomimicking mutants rather than phos-
phodefective Cav-1 and eNOS mutants 
specifically bind to each other. NO and Src-
dependent phosphorylation of Cav-1 there-
fore may be a primary mechanism of eNOS 
negative feedback regulation in endothelial 
cells.
DISCUSSION
Here we demonstrate a novel phospho-
Cav-1–dependent mechanism of eNOS/
Cav-1 binding that mediates eNOS inacti-
vation. eNOS-derived NO production in-
creased Src activity and subsequently the 
phosphorylation of Cav-1 Tyr-14 in en-
dothelial cells, which promoted the bind-
ing of eNOS and Cav-1. Thus these data 
suggest NO production per se negatively 
regulates eNOS activity secondary to Cav-1 
Tyr-14 phosphorylation. The association 
between eNOS and Cav-1, as assessed by 
coIP of endogenous and expressed pro-
teins, was enhanced by Cav-1 Tyr-14 phos-
phorylation and phosphomimicking Y14D 
Cav-1 mutant and blocked by l-NAME, Src 
inhibitor PP2, and Y14F phosphodefective 
mutant. FRET analysis of Cav1-YFP and 
eNOS-CFP, together with measures of 
Ca2+-induced NO production, support the 
hypothesis that p-Tyr-14-Cav-1 provides a 
favorable conformation for CSD-depen-
dent binding of phosphorylated eNOS, re-
sulting in inhibition of eNOS activity. Of in-
terest, in additional studies we observed 
that depletion of Cav-1 from human en-
dothelial cells with siRNA-enhanced Ca2+-
induced eNOS activation (unpublished 
data). However, we also noted decreased eNOS protein level in 
Cav-1 siRNA-treated cells, suggesting that Cav-1 may stabilize 
eNOS and prevent degradation. The mechanism by which Cav-1 
serves to regulate eNOS expression/stability and whether Cav-1 
phosphorylation also plays a role in this process require further 
investigation.
Src kinase activity determined in WT-HEK cells (lacking eNOS) 
showed no change in the Src FRET signal following stimulation 
with A23187 (Figure 5E). These results show that eNOS-derived 
NO activates Src kinase, which phosphorylates Cav-1, leading to 
increased eNOS binding to Cav-1 and inhibition of eNOS 
activity.
FIGURE 5: NO-dependent Src activation mediates Cav-1–Tyr-14 phosphorylation. (A) Decreased 
phosphorylation of Src–Tyr-418 and Cav-1–Tyr-14 in HUVECs after eNOS siRNA treatment (mean 
± SEM; n = 4). Ratio of phosphorylated to total protein at 0 min was set at 1 (*p < 0.05). (B) The 
NO donor DEA NONOate induces Src activation in Cav-1–null MEF cells (mean ± SEM; n = 3). 
After stimulation with 0.2 mM DEA NONOate at indicated times, cells were prepared for 
Western blotting (*p < 0.05). (C) eNOS/NO-dependent Src activation in HEK cells (mean ± SEM; 
n = 7). The ratio of p-Tyr-418-Src at 5 min of A23187 treatment vs. untreated in WT-HEK cells was 
set as 1 (*p < 0.001 vs. WT-HEK). (D) A typical live-cell FRET image of HEK/eNOS cells 
expressing Src FRET biosensor. Fluorescence intensity of CFP and YFP was measured in the ROI 
(white box) before and after treatment with 5 μM A23187. Bar, 10 μm. (E) Activation of Src 
measured by FRET in HEK/eNOS cells expressing Src-FRET biosensor (mean ± SEM; n = 13). 
After cells were pretreated with medium alone, 1 mM l-NAME, or 15 μM PP2 for 30 min at 
37°C, 5 μM A23187 was added and FRET was measured (*p < 0.05 vs. WT-HEK cells; **p < 0.01 
all times beyond 2 min after A23187 addition vs. 0 min).
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phosphodefective eNOS. In contrast, phosphodefective Cav-1 mu-
tant (Cav-1-Y14F) failed to interact with any of the eNOS variants. 
The results of these phosphomimicking and phosphodefective 
Cav-1 and eNOS mutant–binding studies, even with the potential 
caveat that these mutants simply mimic the presence or absence of 
the negatively charged phosphate residue, are consistent with that 
observed with endogenous proteins in the absence and presence of 
Src kinase inhibitor. Our conclusion from these studies is that Cav-1 
phosphorylation at Tyr-14 provides the most favorable conformation 
for eNOS binding and inhibition of eNOS activity.
Ca2+-calmodulin activates eNOS, and high concentration of CaM 
(1 μM) can prevent eNOS/Cav-1 binding in vitro (Bernatchez et al., 
2011). In the present studies, we observed stimulation- and time-
dependent increase in CaM coIP with eNOS following addition of 
Ca2+ ionophore A23187 (Supplemental Figure S3). In this same ex-
periment we observed an increase in the amount of Cav-1 that 
coimmunoprecipitated with eNOS. Data in the literature demon-
strate inhibition of eNOS-derived NO production by Cav-1 or Cav-1 
scaffold domain peptide that can be completely reversed by CaM 
(Ghosh et al., 1998). However, it has not been shown to our knowl-
edge that CaM binding to eNOS promotes release of Cav-1 from 
eNOS. Similarly, whereas addition of Cav-1 or Cav-CSD decreases 
eNOS activity, CaM was not shown to be displaced from eNOS 
(Raman et al., 1998). Thus, since eNOS has separate binding sites 
for CaM (amino acids [aa] 491–510; Michel et al., 1997b) and Cav-1 
(aa 348–356; Couet et al., 1997), data presented here indicate that 
activation of CaM and phosphorylation of Cav-1 increase their bind-
ing to eNOS. In both cases, the binding of either CaM or Cav-1 to 
eNOS is believed to induce a conformational change in the eNOS 
heme-domain activation motif (aa 96–101; Raman et al., 1998).
A distinct feature of these studies was that we monitored interac-
tions between eNOS and Cav-1 by both FRET and coIP. For the 
latter, we used the total membrane fraction (containing virtually 
100% of the total eNOS and Cav-1 protein) instead of membrane-
enriched fractions that contain only a small amount of the total 
eNOS (Supplemental Figure S2). Of interest, coIP of endogenous 
eNOS and Cav-1 from HUVEC total cell lysates increased upon 
Ca2+-dependent stimulation, peaking ∼5 min after treatment with 
A23187. In transfected CHO cells, eNOS–Cav-1 binding also in-
creased upon stimulation with A23187 or thrombin, as shown by 
coIP and FRET. Similarly, we observed increased interaction between 
eNOS and Cav-1 in mouse lungs, indicating the physiological rele-
vance of the cell observations describing the basis of the interaction 
of eNOS with phospho–Cav-1.
A key question that arose from our studies relates to the mecha-
nism of NO-induced Src activation and thereby Cav-1 phosphoryla-
tion on Tyr-14. In HUVECs in which eNOS was depleted by siRNA 
treatment, we observed significantly reduced phosphorylation of 
Src and Cav-1 in response to A23187, in contrast to control cells. It 
is possible that nNOS may be responsible for residual Src activation 
observed in eNOS siRNA or l-NAME–treated cells, as this isoform is 
also expressed in endothelial cells and believed to account for up to 
20% of Ca2+-induced NO release (Bachetti et al., 2004). Further-
more, Src FRET biosensor experiments showed that phosphoryla-
tion and activation of eNOS by addition of A23187 stimulated Src 
activity, which was inhibited by the pharmacological Src inhibitor 
PP2, as well as by eNOS inhibitor l-NAME. Moreover, NO derived 
from an exogenous source, DEA NONOate, induced Src activation, 
consistent with previous reports (Akhand et al., 1999; Monteiro 
et al., 2000) and evidence that NO-mediated S-nitrosylation of Src 
Cys-498 increases Src kinase activity (increase in Src p-Tyr-418) in a 
dose-dependent manner (Raman et al., 1998). It should be noted 
NO is a well-established signaling molecule and key regulator of 
cardiovascular function (Furchgott and Zawadzki, 1980; Huang et al., 
1995). Tight control of NO production is believed to be critically 
important for maintenance of cellular and tissue homeostasis. The 
importance of Cav-1, the primary coat protein of caveolae, in the 
regulation of eNOS activity and NO production has been studied in 
recent years. eNOS localized to the inner leaflet of caveolar mem-
branes and in the Golgi in endothelial cells is believed to be held in 
an inactive state due to direct interaction with Cav-1 (Frank et al., 
2003; Gratton et al., 2004).The binding of eNOS to Cav-1 maintains 
eNOS in its inactive conformation, whereas CaM binding increases 
eNOS activity (Michel et al., 1997a, 1997b; Gratton et al., 2004; Ju 
et al., 1997). eNOS contains a consensus caveolin-binding motif lo-
cated within amino acids 348–356 (García-Cardeña et al., 1997; 
Smart et al., 1999; Couet et al., 1997), and Cav-1 overexpression in 
COS-7 cells decreases eNOS activity (García-Cardeña et al., 1997), 
consistent with the essential role of Cav-1 in restraining eNOS activ-
ity. Several studies have also shown increased NO production in 
Cav1−/− mice and that disruption of the eNOS–Cav-1 complex leads 
to increased eNOS activity and prolonged NO release, which has 
been linked to tissue and organ pathologies (Drab et al., 2001; Zhao 
et al., 2002; Wunderlich et al., 2006; Maniatis et al., 2008; Razani 
et al., 2001). Whether Cav-1 plays a role specifically in the mecha-
nism of eNOS inactivation has not been established.
We addressed the mechanism regulating interaction of eNOS 
with Cav-1 following Ca2+-, VEGF-, and thrombin-induced eNOS 
activation. Cells were treated with agonists to stimulate a rise in in-
tracellular Ca2+ concentration, which was shown to induce eNOS 
activation and production of NO (Jin, 2006). We observed Src kinase 
activation downstream of NO generation, which has been ascribed 
to S-nitrosylation of Src at Cys-498 (Raman et al., 1998). The resul-
tant phosphorylation of eNOS Ser-1177 and Cav-1 Tyr-14 increased 
eNOS/Cav-1 binding, which was associated with a decrease in 
eNOS activity. This was evident from results showing that WT-Cav-1 
interacted equally well with WT-eNOS and with phosphomimicking 
or phosphodefective eNOS mutants expressed in HEK cells, whereas 
the phosphomimicking Cav-1 mutant (Cav-1-Y14D) interacted 
strongly with WT-eNOS and phosphomimicking eNOS but not with 
FIGURE 6: Proposed mechanism of negative feedback regulation of 
eNOS by phospho–Cav-1. Ca2+-dependent stimulation of endothelial 
cells induces eNOS activation by phosphorylation on Ser-1177, and 
NO is released within 1 min. NO induces Src activation and 
phosphorylation of Cav-1 on Tyr-14, which we propose leads to 
unmasking of the caveolin scaffolding domain. Phosphorylated Cav-1 
then binds to activated eNOS, inhibiting eNOS activity, and release of 
NO, thus returning eNOS to its basal state. eNOS/Cav-1 interaction 
can be blocked by eNOS inhibitor l-NAME and Src inhibitor PP2, 
suggesting that an NO/Src-dependent feedback mechanism mediates 
eNOS inactivation.
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mammalian expression vectors pcDNA3 and pcDNA6, and Geneti-
cin were purchased from Invitrogen (Carlsbad, CA). The vectors 
for CFP and YFP were obtained from Clontech (Palo, Alto, CA). 
Mouse anti-eNOS, rabbit anti–caveolin-1, mouse anti–Tyr-14-caveo-
lin-1, rabbit and mouse immunoglobulin G, and mouse anti-actin 
were from BD Biosciences (San Diego, CA). Rabbit anti–phospho-
Tyr-418-Src, rabbit anti-eNOS, rabbit anti–phospho-Ser-1177-eNOS, 
rabbit anti–phospho-Ser-473-Akt, and rabbit anti–phospho-
Thr-308-Akt were from Cell Signaling Technology (Danvers, MA). 
Rabbit anti–c-Src and anti-AKT antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Mouse anti-CaM was from 
Millipore (Temecula, CA).
Construction of Cav-1-YFP, Cav-1-Y14D-YFP, 
and Cav1-Y14F-YFP plasmids
To generate the wild-type, C-terminal, YFP-tagged caveolin-1 
(Cav-1-YFP), full-length Homo sapiens Cav-1 was used as a 
template in a PCR with DNA Phusion High-Fidelity Polymerase 
(New England BioLabs, Ipswich, MA), using the following 
primer pair lacking the stop codon: Cav1-WT-F:5′-ACTAGCTAG
CGACCGCCATGTCTGGGGGCAAAT-AC-3′ and Cav-1-WT-R:5′-
ACTGGGTACCGTTATTTC-TTTCTGCAAGTTGATGCG-3′. The re-
sulting PCR fragment was digested with restriction enzymes 
5′-NheI and 3′-KpnI (italicized in the primers) and subcloned 
into pEYFP-N1 vector (Clontech, Mountain View, CA).
To generate the Cav-1-Y14D-YFP plasmid, a two-step PCR method 
was used. In the first step, two PCR fragments were generated using 
the wild-type caveolin 1 cDNA as the DNA template and the follow-
ing primer pairs: fragment A, primer pairs Cav-1-WT-F and Cav-1-
Y14D-R-5′-ATGGGAACGGTGTCGAGATGTCC-3′, and fragment B, 
primer pairs Cav-1-Y14D-R-5′-ATGGGAACGGTGTCGAGATGTCC-3′ 
and Cav-1-WT-R. As shown in the primers, the underlined base pair 
resulted in Y14-to-D14 mutation. In the second step, a final PCR 
product, fragment C, was generated by combining fragments A and 
B together as PCR DNA templates with primer pair Cav-1-WT-F and 
Cav-1-WT-R. The fragment C was digested with NheI and KpnI li-
gated at the same restriction sites of pEYFP-N1 vector.
Similar to the Y14D plasmid, the Cav-1-Y14F-YFP plasmid was 
generated in the first PCR step using primer pairs for fragment A, Cav-
1-WT-F and Cav-1-Y14F-R-5′-ATGGGAACGG-TAAAGAGATGTCC-3′, 
and Cav-1-Y14F-F-5′-GGACATCTCTTTACCGT-TCCCAT-3′ and Cav1-
WT-R for fragment B. Fragment C was generated with primer pairs 
Cav-1-F and Cav-1-R and both fragments A and B as DNA templates. 
Fragment C was digested and ligated as described. All resulting plas-
mids were verified and analyzed by gel analysis and sequencing 
analysis.
Construction of pcDNA3-eNOS-CFP, pcDNA3-eNOS-
S1177D-CFP, and pcDNA3-eNOS-S1177A-CFP plasmids
The 5′-NheI/3′-SmaI fragment of CFP from pECFP-C1 (Clontech) 
was subcloned into pACGp67A (BD Biosciences) at the 5′-XbaI/ 
3′-EcoRI sites, creating pACGp67A-CFP. The CFP fragment was 
then excised at 5′-BamHI/ 3′-NotI sites from the pACGp67A-CFP 
and ligated at the same restriction sites into pcDNA3 (Invitrogen), 
creating pCDNA3-CFP. To create the vector eNOS with CFP tagged 
at the C-terminus, full-length H. sapiens eNOS cDNA (with GenBank 
Accession number NM_000603 from OriGene Technologies, 
Rockville, MD) was used as DNA template in a PCR to generate 
eNOS PCR fragment that contained AgeI at both 5′ and 3′ ends. 
The 5′/3′-AgeI fragment of eNOS was then digested and ligated to 
the same restriction sites on the pcDNA3-CFP vector to create the 
pcDNA3-eNOS-CFP plasmid. The primers used were eNOS-AgeI-F, 
here that phosphorylated Cav-1 also functions as a negative regula-
tor of Src activity by facilitating the recruitment of C-terminal Src ki-
nase (Csk), which is known to phosphorylate Src-negative regulatory 
Tyr-529 and induce Src inactivation (Place et al., 2011).
The functional significance of Cav-1 Tyr-14 phosphorylation was 
previously linked to tumor cell migration (Joshi et al., 2008), modu-
lation of focal adhesion (Grande-García et al., 2007), mechanotrans-
duction (Radel et al., 2007), and caveolae formation and endocyto-
sis (Minshall et al., 2000; Shajahan et al., 2004; Orlichenko et al., 
2006; Hu et al., 2006, 2008; Sverdlov et al., 2007, 2009; Sun et al., 
2009). Data presented here indicate that pTyr-14-Cav-1 may obtain 
a favorable conformation that leads to enhanced docking of pro-
teins, presumably via the CSD, thus enabling recruitment of proteins 
to caveolae, where signaling can be regulated. We posit that a neg-
ative feedback mechanism that returns eNOS activity to its ground 
state may be pathophysiologically important in vascular inflamma-
tion, which is often associated with dysregulated eNOS activity, per-
sistent NO production, and NO modification of endothelial regula-
tory proteins (Siddiqui et al., 2011).
MATERIALS AND METHODS
Cell culture and transfection
HUVECs were purchased from Vec Technologies (Rensselaer, NY). 
Cav-1–null and WT mouse embryonic fibroblasts, HEK 293, and 
CHO-K1 cells were from the American Type Culture Collection 
(Rockville, MD). HUVEC growth medium (EGM-2 plus Bullet kit) 
was from Lonza (Walkersville, MD). Nitrocellulose membrane was 
from Bio-Rad Laboratories (Hercules, CA). Supersignal West Femto 
Kit and Restore Western Stripping buffer were from Pierce (Rockford, 
IL). HAM’s F-12 (for CHO cells) and DMEM (for HEK 293 cells and 
MEFs) were from Invitrogen (Grand Island, NY). Fetal bovine serum 
(FBS) was from Serum Source International (Charlotte, NC). Geneti-
cin was purchased from Invitrogen (Carlsbad, CA). The 96-well assay 
plate for NO measurement was from Corning (Corning, NY).
HUVECs were cultured in EGM-2 medium (Lonza) supplemented 
with 10% (vol/vol) FBS, split 1:4 upon reaching confluence, and used 
at passages 5–7. For immunofluorescence microscopy, cells were 
grown on noncoated glass coverslips. For DAF-2 DA experiments, 
cells were grown in black, clear-bottom, 96-well plates (Costar, 
Acton, MA,). CHO cells were cultured in Ham’s F-12 medium sup-
plemented with 10% FBS and 1% penicillin/streptomycin. HEK 293 
and MEF cells were cultured in DMEM supplemented with 10% FBS 
and 1% penicillin/streptomycin. cDNAs of Cav-1 or eNOS mutants 
were transfected in CHO or HEK 293 cells using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. Cells 
were selected with Geneticin 24–36 h after transfection. Stable cell 
lines were obtained by fluorescence-activated cell sorting plating 
and growth of single cells in 96-well plates in presence of Geneticin. 
Cells transduced with fluorescently tagged proteins were verified by 
fluorescence microscopy and immunoblot analysis.
Reagents
PP2, A23187 (calcimycin), l-NAME, and H89 were from Sigma-Al-
drich (St. Louis, MO). Human α-thrombin was from Enzyme Research 
Laboratories (South Bend, IN). 4,5-DAF-2 DA, 5-iodotubercidin, and 
STO-609 were from Calbiochem (La Jolla, CA). Recombinant human 
VEGF-165 was from Shenandoah Biotechnology (Warwick, PA). 
Glass-bottom dishes for live-cell images were from MatTek (Ashland, 
MA). DEA NONOate was from A.G. Scientific (San Diego, CA). 
n-Octyl-β-d-glucopyranoside (ODG) was from RPI Corp. (Mt. Pros-
pect, IL). siRNA of eNOS and transfection reagent DharmaFect 1 
were from Dharmacon (Lafayette, CO). DAPI, Lipofectamine 2000, 
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described previously (Chen et al., 2006). Two images of the basal 
fluorescence were collected before addition of stimulus. Intensity of 
donor and acceptor emission was determined from selected ROIs 
and was averaged and plotted as acceptor/donor (YFP/CFP) as an 
index of Src biosensor activity (Wang et al., 2005) or donor/acceptor 
(CFP/YFP) to reflect temporal changes in eNOS/Cav-1 FRET.
siRNA-mediated eNOS depletion
Confluent HUVECs seeded in 35-mm wells were grown to ∼40% 
confluence and transfected with eNOS or scrambled siRNA at a final 
concentration of 100 nM. After 72 h, cells were stimulated and lysed 
for Western blot analysis.
Immunoprecipitation and Western blotting
After treatment with different reagents, cells were lysed by sonica-
tion in 2% ODG in Tris buffer (pH 7.50, 50 mM Tris, 150 mM NaCl, 
1 mM NaF, 1 mM EDTA, 1 mM Na3VO4, 44 μg/ml phenylmethylsul-
fonyl fluoride [PMSF], 1% protease inhibitor cocktail). The lysates 
were centrifuged for 20 min at 16,000 × g at 4°C. Supernatants were 
collected for IP or Western blot analysis. For IP, antibodies were 
added to the cell lysates in 1.5-ml Eppendorf tubes and rotated 
overnight at 4°C and then rotated for 2 h at 4°C with protein A 
beads. The beads were washed five times with Tris buffer containing 
1% ODG. The proteins were eluted with Laemmli buffer, subjected 
to SDS-PAGE, transferred to nitrocellulose membranes, and probed 
with primary and secondary antibodies. Membrane-bound antibod-
ies were visualized using Supersignal West Femto Kit.
Phosphorylation of eNOS (Ser-1177), Src (Tyr-418), Cav-1 
(Tyr-14), and Akt (Thr-308, Ser-473) after stimulation with 
A23187
After serum deprivation in culture medium containing 0.5% FBS 
overnight or 0.1% FBS for 5–7 h, cells were washed three times with 
serum-free medium. Agonists were added to the cells at indicated 
times and incubated at 37°C. For inhibitor experiments, inhibitors 
were added 30 min prior to stimulation. Finally, after washing once 
with ice-cold Tris buffer (50 mM Tris, 150 mM NaCl, 1 mM NaF, 
1 mM EDTA, 1 mM Na3VO4, 44 μg/ml PMSF, pH 7.50), the cells 
were collected and lysed for Western blotting or IP.
Comparison of membrane fractions for coIP experiment 
in HUVECs
Membrane-enriched fractions of HUVEC were prepared for coIP as 
described (Busconi and Michel, 1993; Feron et al., 1998), but with 
the following modifications. Briefly, after treatment with vehicle or 
5 μM A23187 for 3 min at 37°C, cells were collected and sonicated 
in phosphate-buffered saline (containing 1% protease inhibitor 
cocktail) and centrifuged at 100,000 × g for 30 min at 4°C. The su-
pernatants (cytosolic fraction) were collected, and pellets were dis-
solved in 2% ODG in Tris buffer and centrifuged again for 30 min at 
100,000 × g. The supernatants (membrane-enriched fraction) were 
collected and the pellets were dissolved in RIPA buffer (150 mM 
NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
and 50 mM Tris, pH 8.0) by sonication. Insoluble fractions after ODG 
were collected by centrifugation for 10 min at 1000 × g. For isolation 
of the total membrane fraction, cells were dissolved in 2% ODG (Tris 
buffer) by sonication, and supernatants (total membrane fraction) 
were collected after centrifugation for 20 min at 16,000 × g. The 
pellets were then dissolved by sonication in RIPA buffer. Superna-
tants (insoluble fractions in ODG) were cleared by centrifugation for 
10 min at 1000 × g, and then all fractions were prepared for immu-
noblotting or IP.
5′-ATTATAACCGGTAGCCACCATGGGCAACTTGAAG-AG-3′; and 
eNOS-NoSTOP-AgeI-R, 5′-ATTATAACCGGTAGGGGGCTGTTGGT-
GTCTGAG-3′.
For the mutation of serine 1177 in eNOS, a two-step PCR method 
was used. In the first step, two PCR fragments were generated by 
PCR using eNOS cDNA as DNA template. For the generation of 
pCDNA3-eNOS-S1177D-CFP plasmid, the following primers were 
used: for fragment A, primer pair eNOS-AgeI-F and eNOS-S1177D-
R:5′-CTGACGCTCCTGCAAG-TCAAAGCTC-TG-3′; for fragment B, 
primer pair, eNOS-S1177D-F:5′-TACGCACCCAGA-GCTTTGACTT-
GCAGGAG-3′ and eNOS-NoStop-AgeI-R. Underlined base pairs 
indicated sites of amino acid point mutation. In the second step, a 
final PCR product, fragment C, was generated by combining frag-
ments A and B together as PCR DNA templates with primer pair 
eNOS-AgeI-F and eNOS-NoSTOP-AgeI-R. PCR fragment C was 
then digested and ligated as described to create pCDNA3-eNOS-
S1177D-CFP plasmid.
Similarly, the pCDNA-eNOS-S1177A-CFP plasmid was gener-
ated in the first PCR step using primer pairs for fragment A, eNOS-
AgeI-F and eNOS-S1177A-R:5′-CTGACGCTCCT-GCAAGGCAAA-
GCTCTG-3′; and for fragment B, eNOS-S1177A-F:5′-TACGCACC-
CAGA-GCTTTGCCTTGCAGGAG-3′ and eNOS-NoStop-AgeI-R. 
Fragment C was generated with primer pair eNOS-AgeI-F and 
eNOS-NoStop-AgeI-R using both fragments A and B as DNA tem-
plates. The resulting PCR fragment C was also digested and li-
gated as described, creating pCDNA-eNOS-S1177A-CFP plasmid. 
All generated plasmids were verified and analyzed by gel analysis 
and sequencing analysis.
Analysis of eNOS activity by DAF-2 fluorescence
Intracellular NO measurement using the NO-specific fluorescence 
probe DAF-2 DA was described previously (Nakatsubo et al., 1998; 
Kojima et al., 1998). Briefly, after incubation in serum-free EGM-2 
(containing 0.1% BSA) overnight, endothelial cells on 96-well plates 
were washed with Krebs–Ringer phosphate (KRP) buffer (120 mM 
NaCl, 4.8 mM KCl, 0.54 mM CaCl2, 1.2 mM MgSO4, 11 mM glucose, 
15.9 mM sodium phosphate, pH 7.20), incubated with 5 μM DAF-2 
DA in KRP buffer for 30 min at room temperature, washed again with 
KRP buffer, and then incubated with KRP buffer for 30 min at 37°C in 
the absence or presence of 1 mM l-NAME, after which calcium iono-
phore A23187, thrombin, VEGF, or KRP buffer was added to the 
wells. Fluorescence (emission wavelength, 485 nm; excitation wave-
length, 538 nm) was measured temporally at 37°C from 0 to 60 min 
using the bottom-reading mode in a FlexStation II plate reader 
(Molecular Devices, Sunnyvale, CA). DAF-2 DA experiments were 
repeated at least three times, and eight wells were used in each 
experiment.
Chemiluminescence-based NO measurements
HUVECs were washed twice with HBSS and incubated with HBSS-
Arg (HBSS plus 0.2–0.5 mM l-arginine) for 30 min at 37°C. The cells 
were then treated with agonists for up to 30 min in HBSS-Arg. NO 
concentration in the culture media was assessed by measuring NO2
− 
accumulation as described (Bonini et al., 2002), using a Sievers NO 
Analyzer (Sievers Instruments, Boulder, CO). NO release from trans-
fected HEK cells was assessed from NO2
− level in the media (Michel 
et al., 1997a; Bernatchez et al., 2005) and reported as μmol NO2
−/
min per 106 cells.
Fluorescence resonance energy transfer
Cells cultured on glass-bottom dishes were imaged with a Zeiss 
LSM-510 META confocal microscope (Carl Zeiss, Jena, Germany) as 
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Mouse lung preparations
Anesthetized mice were killed and lungs perfused via pulmonary 
artery cannula with DMEM/F-12 medium (without FBS) for 10 min at 
0.2 ml/min at 37°C. Lungs were then perfused with medium con-
taining 5 μM A23187 for 0, 3, and 10 min and then rinsed with cold 
medium containing phosphatase inhibitors for another 3 min. Lungs 
were homogenized and sonicated in Tris buffer containing 2% ODG. 
Lysates were centrifuged for 20 min at 16,000 × g at 4°C, and super-
natants were collected for immunoblotting or IP.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was per-
formed by Student’s t test or one-way analysis of variance using 
Graph InStat software (San Diego, CA).
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